Talk:Duvelisib
This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||
|
The following Wikipedia contributor may be personally or professionally connected to the subject of this article. Relevant policies and guidelines may include conflict of interest and neutral point of view.
|
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Duvelisib.
|
Patents
[edit]I haven't seen a table of patent info in other drug articles, so I'm wondering if it adds relevant info to the article here. It's an article about an experimental drug, so I can see the argument for including it because the topic is different than that of marketed drugs, but I'd like other opinions. Natureium (talk) 15:19, 19 January 2017 (UTC)
- Very happy to see that gone. It is taken from pubchem which is not necessarily reliable for this subject of patents, and who ever added it to this article made some selection of patents listed in pubchem that is basically OR. Jytdog (talk) 17:35, 19 January 2017 (UTC)
The long and twisty path to Verastem
[edit]Robert Forrester, CEO of Verastem, answered some questions about the way Duvelisib ended up at Verastem in the Nov 14, 2017 in the Q&A after his presentation at the Jefferies healthcare conference, and there is more to it than is explained in the wikipedia article. Some of it is hard to make out on the webcast, but it sounds extremely interesting. (Anyone can see the webcast, but this sort of presentation tends to disappear from the webcast after some small number of months.) 108.45.80.41 (talk) 08:47, 18 November 2017 (UTC)
This drug was considered as 'failed' by infinity, as NHL results in the duo study were not as planned. (There is a on almost emotional PR from Infinity on this). The CLL trial was ongoing, and the compound sold to Verastem, for little money. This year, the CLL trial had been found to be successful. Wowbagger2 (talk) 14:46, 27 December 2017 (UTC)
Request to add the sentence per FDA approval
[edit]This edit request by an editor with a conflict of interest was declined. Please see the Reply section below for additional information about your request. |
Duvelisib, sold under the trade name Copiktra™, is a medication approved to treat a number of different forms of blood cancers. Citation: FDA https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm621503.htm— Preceding unsigned comment added by 136.24.42.57 (talk) 20:55, 18 October 2018 (UTC)
- I agree that approval should be added at some point, but together with a comprehensive overview of efficacy and safety!Wowbagger2 (talk) —Preceding undated comment added 06:53, 19 October 2018 (UTC)
- Medical Uses
- It is indicated for adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma (FL) who have received at least two prior therapies.
- Adverse Effects
- The U.S. label for duvelisib has a boxed warning describing side effects that can be serious and fatal including infections, diarrhea or inflammation of the intestines, skin reactions, and inflammation of the lungs. Other serious side effects include abnormal liver blood tests and low white blood cell counts (neutropenia).
- Reference: FDA [1] — 136.24.42.57 (talk) 15:56, 23 October 2018 (UTC) comment added 08:53, 23 October 2018 (UTC)
- As it has a boxed warning, the current already performed edits I highly recommend to delete - someone neutral person needs to take care of this article!
- Without this relevant label information, I think the article should not include commercial information Wowbagger2 (talk) 07:10, 24 October 2018 (UTC)
Reply 24-OCT-2018
[edit] Unable to review edit request
Your edit request could not be reviewed because the request is not formatted correctly.
- The citation note numbers are not placed within the requested text indicating which portions of the text the source is referencing. (See WP:INTEGRITY.)
- The citation style predominantly used by the Duvelisib article appears to be Citation Style 1. The citation style used in the edit request consists of bare URL's.[a] Any requested edit of yours which may be implemented will need to resemble the current style already in use in the article – in this case, CS1. (See WP:CITEVAR.)
In the collapsed section below titled Request edit examples, I have illustrated two: The first shows how the edit request was submitted; the second shows how requests should be submitted in the future.
Request edit examples
|
---|
In the example above there are three URL's provided with the claim statements, but these URL's have not been placed using Citation Style 1, which is the style predominantly used by the Duvelisib article. Additionally, the references have not been placed within the text at the exact positions where the information they reference resides. Using the correct style and the correct positioning of the ref notes, the WikiFormatted text would resemble the following:
In the example above the references have been formatted according to Citation Style 1, which shows the author, the source's name, date, etc. Also, the reference notes are placed in the exact location where the text which they reference resides. As Wikipedia is a volunteer project, edit requests such yours are generally expected to have this formatting done before the request is submitted for review. |
Kindly rewrite your edit request so that it aligns more with the second example shown in the collapsed section above, and feel free to re-submit that edit request at your earliest convenience. If you have any questions about this formatting please don't hesitate to ask myself or another editor. Regards, Spintendo 04:52, 11 October 2018 (UTC)
Notes
- ^ The use of bare URLs as references is a style which is acceptable for use in Wikipedia. However, general practice dictates that the style already in use for an article be the one that is subsequently used for all future additions unless changed by editorial consensus. (See WP:CITEVAR.)
- Start-Class medicine articles
- Mid-importance medicine articles
- All WikiProject Medicine pages
- Start-Class pharmacology articles
- Mid-importance pharmacology articles
- WikiProject Pharmacology articles
- Start-Class chemicals articles
- Low-importance chemicals articles
- Articles edited by connected contributors
- Declined requested edits